Showing results (41-50 of 182) with videos related to
Sort By:
Pageof 19
Neurourology and Urodynamics|April 12, 2002
Identifying cut-off scores with neural networks for interpretation of the incontinence impact questionnaireJacques Corcos, Hassan Behlouli, Sylvie BeaulieuAnnals of Physical and Rehabilitation Medicine|June 18, 2017
What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world?Mikolaj Przydacz, Pierre Denys, Jacques CorcosAge and Ageing|July 1, 2008
Rating improvements in urinary incontinence: do patients and their physicians agree?Cara Tannenbaum, Judith Brouillette, Jacques CorcosInternational Urogynecology Journal|August 8, 2013
What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?Romain Caremel, Oleg Loutochin, Jacques CorcosCanadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 24, 2014
Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosisOussama El Yazami Adli, Jacques CorcosInternational Urology and Nephrology|March 24, 2018
Recommendations for urological follow-up of patients with neurogenic bladder secondary to spinal cord injuryMikolaj Przydacz, Piotr Chlosta, Jacques CorcosBMJ Case Reports|July 7, 2025
From immunotherapy to autoimmunity: reactive arthritis following intravesical BCGSaad Alqasem, Sophie Wojcik, Jacques CorcosUrology|October 19, 2005
Understanding detrusor sphincter dyssynergia--significance of chronologyGilles Karsenty, Andre Reitz, Bjorn Wefer, et al.Revue Medicale Suisse|January 15, 2014
[Benefit of a specialized multidisciplinary clinic in neuro-urology and functional urology]Cécilie Tawadros, Thomas Tawadros, Loïc Julita, et al.Urology|December 5, 2006
Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivityGilles Karsenty, André Reitz, Gertraud Lindemann, et al.Pageof 19